Literature DB >> 24817963

Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.

Veronica Bernard1, Niklas Gebauer1, Thomas Dinh1, Judith Stegemann1, Alfred C Feller1, Hartmut Merz1.   

Abstract

Decalcified formalin-fixed and paraffin-embedded (dFFPE) bone marrow trephines remain the primary source of gDNA in hematopathological diagnostics. Here, we investigated the applicability of next-generation sequencing (NGS) to dFFPE samples. Chronic myelomonocytic leukaemia (CMML) is a haematopoietic stem cell malignancy delineated by genetic heterogeneity. Recently characteristic mutations have been identified for this entity in a distinct group of genes (TET2, CBL, KRAS). We comparatively investigated DNA extracted from fresh mononuclear cells as well as dFFPE samples from four CMML patients employing a commercially available primer set covering the above mentioned and well characterized mutational hotspots in CMML followed by an amplicon based next-generation deep-sequencing (NGS) approach. As we observed high quality run data as well as complete concordance between both sample types in all cases, we further validated the potential of NGS in hematopathology on a larger cohort of CMML patients (n=39), detecting sequence variations in 84.6% of patients. Sequence analysis revealed 92 variants, including five known polymorphisms, ten silent mutations, 36 missense mutations, 14 nonsense mutations, 24 frame shift mutations and three potential splice site mutations. Our findings ultimately demonstrate the applicability of NGS to dFFPE biopsy specimen in CMML and thus allowing the pathologist to evaluate prognostically relevant mutations at a high resolution and further contribute to risk stratification for the individual patient.

Entities:  

Keywords:  Next-generation sequencing; chronic myelomonocytic leukaemia; decalcified; formalin-fixed; paraffin-embedded samples

Mesh:

Substances:

Year:  2014        PMID: 24817963      PMCID: PMC4014247     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  30 in total

1.  Prognostic significance of monocytosis in patients with myeloproliferative disorders.

Authors:  Miloslav Beran; Yu Shen; Francesco Onida; Sijin Wen; Hagop Kantarjian; Elihu Estey
Journal:  Leuk Lymphoma       Date:  2006-03

2.  Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System.

Authors:  Miloslav Beran; Sijin Wen; Yu Shen; Francesco Onida; Jaroslav Jelinek; Jorge Cortes; Francis Giles; Hagop Kantarjian
Journal:  Leuk Lymphoma       Date:  2007-06

3.  High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Authors:  Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross L Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc M Loriaux
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

4.  Unlocking pathology archives for microRNA-profiling.

Authors:  Kai P Hoefig; Christoph Thorns; Anja Roehle; Christian Kaehler; Kai O Wesche; Dirk Repsilber; Biggi Branke; Marlen Thiere; Alfred C Feller; Hartmut Merz
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

5.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.

Authors:  A Tefferi; R L Levine; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; C M Finke; A Mullally; C-Y Li; A Pardanani; D G Gilliland
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

6.  Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors.

Authors:  P Fenaux; J P Jouet; M Zandecki; J L Lai; M Simon; J P Pollet; F Bauters
Journal:  Br J Haematol       Date:  1987-01       Impact factor: 6.998

7.  Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Groupe Français de Cytogénétique Hématologique.

Authors: 
Journal:  Cancer Genet Cytogenet       Date:  1991-08

8.  The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H Gralnick; C Sultan; C Cox
Journal:  Br J Haematol       Date:  1994-08       Impact factor: 6.998

Review 9.  CMML: a biologically distinct myeloproliferative disease.

Authors:  Jorge Cortes
Journal:  Curr Hematol Rep       Date:  2003-05

10.  Chronic myelomonocytic leukemia in the light of the WHO proposals.

Authors:  Ulrich Germing; Corinna Strupp; Sabine Knipp; Andrea Kuendgen; Aristoteles Giagounidis; Barbara Hildebrandt; Carlo Aul; Rainer Haas; Norbert Gattermann; John M Bennett
Journal:  Haematologica       Date:  2007-07       Impact factor: 9.941

View more
  3 in total

1.  GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site.

Authors:  Shaoyong Lu; Avik Banerjee; Hyunbum Jang; Jian Zhang; Vadim Gaponenko; Ruth Nussinov
Journal:  J Biol Chem       Date:  2015-10-09       Impact factor: 5.157

2.  Targeted sequencing of candidate gene regions for myelofibrosis in dogs.

Authors:  Amelia G Campbell; Davis M Seelig; Joan D Beckman; Katie M Minor; Daniel A Heinrich; Steven G Friedenberg; Jaime F Modiano; Eva Furrow
Journal:  J Vet Intern Med       Date:  2022-07-11       Impact factor: 3.175

3.  Comprehensive Molecular Profiling of Archival Bone Marrow Trephines Using a Commercially Available Leukemia Panel and Semiconductor-Based Targeted Resequencing.

Authors:  Stephan Bartels; Elisa Schipper; Hans Heinrich Kreipe; Ulrich Lehmann
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.